Mechanisms responsible for malignant melanoma progression to highly aggressive brain-metastatic disease remain largely unknown. We have previously demonstrated that certain neurotrophins (NT) and their receptor p75 TR modulate the invasion of melanoma cells to the brain and the activity of an enzyme, called heparanase. This enzyme is a key determinant for the successful degradation of the tumor-surrounding extracellular matrix (ECM): heparanase degrades heparan sulfate proteoglycans (HSPGs), which are important ECM components, at sites within HS linear chains. Our hypothesis is that NT/p75NTR play important roles in melanoma brain invasion and that NT-regulated heparanase is critical in the metastatic melanoma progression being a potential target for antimetastasis drugs. The objective of this application is to determine p75NTR function as a molecular determinant of brain metastases formation and the role of heparanase in invasion and angiogenesis. We selected melanoma cells with low/high p75NTR expression and generated a monoclonal antibody against human heparanase that inhibits its enzymatic activity and experimental metastases formation. In addition, we have access to the recently cloned human heparanase, related probes, and novel important enzyme inhibitors.
Our specific aims are: 1. To define p75NTR as a molecular determinant of brain-metastatic melanoma cells, which will be accomplished by modifying p75NTR gene expression and analysis of p75NTR variants for their organ colonizing abilities in nude mice, in particular to the brain. 2. To characterize NT-regulated heparanase gene expression at specific steps of metastasis in malignant melanoma, which will be accomplished by studying the distribution and mechanisms of human heparanase to test the precise function of heparanase in the multistep process of melanoma metastasis. 3. To determine the role of heparanase in angiogenesis, which will be accomplished by relating angiogenic molecules and models to heparanase functionality by using purified enzyme and HS substrates subpopulations from corresponding HSPGs. We anticipate that the results of our proposed research will fundamentally advance the field of brain tumors biology and metastatic ECM processing. Of significance, they are expected to provide new targets for preventive and therapeutic interventions that will be particularly important to the growing numbers of persons who have malignant melanoma, and are experiencing the """"""""urgency"""""""" of the melanoma problem.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
7R01CA086832-02
Application #
6557538
Study Section
Pathology B Study Section (PTHB)
Project Start
2001-07-01
Project End
2006-02-28
Budget Start
2002-03-01
Budget End
2003-02-28
Support Year
2
Fiscal Year
2001
Total Cost
$244,020
Indirect Cost
Name
Louisiana State University A&M Col Baton Rouge
Department
Veterinary Sciences
Type
Schools of Veterinary Medicine
DUNS #
075050765
City
Baton Rouge
State
LA
Country
United States
Zip Code
70803
Vishnoi, Monika; Boral, Debasish; Liu, Haowen et al. (2018) Targeting USP7 Identifies a Metastasis-Competent State within Bone Marrow-Resident Melanoma CTCs. Cancer Res 78:5349-5362
Ridgway, Lon D; Wetzel, Michael D; Ngo, Jason A et al. (2012) Heparanase-induced GEF-H1 signaling regulates the cytoskeletal dynamics of brain metastatic breast cancer cells. Mol Cancer Res 10:689-702
Ridgway, Lon D; Wetzel, Michael D; Marchetti, Dario (2011) Heparanase Modulates Shh and Wnt3a Signaling in Human Medulloblastoma Cells. Exp Ther Med 2:229-238
Zhang, Lixin; Sullivan, Peggy S; Goodman, Jerry C et al. (2011) MicroRNA-1258 suppresses breast cancer brain metastasis by targeting heparanase. Cancer Res 71:645-54
Zhang, Lixin; Sullivan, Peggy; Suyama, Julie et al. (2010) Epidermal growth factor-induced heparanase nucleolar localization augments DNA topoisomerase I activity in brain metastatic breast cancer. Mol Cancer Res 8:278-90
Ridgway, Lon D; Wetzel, Michael D; Marchetti, Dario (2010) Modulation of GEF-H1 induced signaling by heparanase in brain metastatic melanoma cells. J Cell Biochem 111:1299-309
Roy, Madhuchhanda; Marchetti, Dario (2009) Cell surface heparan sulfate released by heparanase promotes melanoma cell migration and angiogenesis. J Cell Biochem 106:200-9
D'Souza, Sonia; Yang, Weidong; Marchetti, Dario et al. (2008) HIP/RPL29 antagonizes VEGF and FGF2 stimulated angiogenesis by interfering with HS-dependent responses. J Cell Biochem 105:1183-93
Marchetti, D; Mrak, R E; Paulsen, D D et al. (2007) Neurotrophin receptors and heparanase: a functional axis in human medulloblastoma invasion. J Exp Clin Cancer Res 26:5-23
Reiland, Jane; Kempf, Doty; Roy, Madhuchhanda et al. (2006) FGF2 binding, signaling, and angiogenesis are modulated by heparanase in metastatic melanoma cells. Neoplasia 8:596-606

Showing the most recent 10 out of 18 publications